Concepedia

Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis

Paul Y. Kwo, Fred Poordad, Armen Asatryan, Stanley Wang, David Wyles, Tarek Hassanein, Franco Felizarta, Mark Sulkowski, Edward Gane, Benedict Maliakkal,

Journal of Hepatology · 2017 · 297 citations · 13 references

DOIFull text

Open access

Concepts

References

13

Global distribution and prevalence of hepatitis C virus genotypes

Jane P. Messina, Isla Humphreys, Abraham D. Flaxman et al. · Hepatology · 2014 · 1.6K citations · Full text

, , +16

Grazoprevir–Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection

Stefan Zeuzem, Reem Ghalib, K. Rajender Reddy et al. · Annals of Internal Medicine · 2015 · 517 citations

, , +17

The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm

Homie Razavi, Imam Waked, Christoph Sarrazin et al. · Journal of Viral Hepatitis · 2014 · 484 citations · Full text

, , +16

<i>In Vitro</i> Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir

Teresa I. Ng, Preethi Krishnan, Warren M. Kati et al. · Antimicrobial Agents and Chemotherapy · 2017 · 139 citations · Full text

, , +17

<i>In Vitro</i> and <i>In Vivo</i> Antiviral Activity and Resistance Profile of Ombitasvir, an Inhibitor of Hepatitis C Virus NS5A

Preethi Krishnan, Jill Beyer, Neeta Mistry et al. · Antimicrobial Agents and Chemotherapy · 2014 · 131 citations · Full text

, , +17